Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Intracameral injection of Triamcinolone Acetonide during cataract surgery in eyes with uveitis

Poster Details

First Author: M.Attzs UK

Co Author(s):    A. Puiu   S. Srinivasan   M. Varikkara              

Abstract Details


To evaluate the efficacy and safety on the use of preservative containing intracameral triamcinolone acetonide (ICTA) during cataract surgery, in patients with visually significant cataract and history of uveitis.


District General Hospital, Scotland


Prospective interventional case series. 9 eyes of 9 patients with previous uveitis underwent cataract surgery with 0.01 ml ICTA (Kenalog, 4 mg / 0.1 mL) injected at the end of cataract surgery. None of the patients received topical steroids in the post operative period. All eyes were free of intraocular inflammation for at least six months prior to the cataract surgery. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, and intraocular pressure (IOP) were evaluated pre and post operatively. All patients had pre and post operative endothelial cell density measurements, with a mean follow- up of 19.2 months.


Mean age of the cohort was 68 ± 11years (range 50-82). Mean improvement in UDVA was 0.62 logMAR. Pre operative mean endothelial cell count was 2300 ± 458 cells/mm2. At a mean follow up of 19.2 ± 13.7 months, mean endothelial cell loss was 8.6%. No intraocular pressure spikes were noted up to 6 months post operatively in our study group. One patient developed cystoid macular oedema postoperatively, and two patients had a recurrence of uveitis within the 6 months following cataract surgery.


Preservative containing 0.01 ml intracameral triamcinolone acetonide (Kenalog, 4 mg / 0.1 mL) appears to be safe and effective as an intracameral agent, without detriment to corneal endothelial cell density during cataract surgery in uveitic eyes.

Financial Disclosure:


Back to Poster listing